RedHill Biopharma (RDHL) EPS (Basic): 2012-2023
Historic EPS (Basic) for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $0.05.
- RedHill Biopharma's EPS (Basic) rose 163.44% to $0.05 in Q2 2023 from the same period last year, while for Jun 2023 it was -$0.11, marking a year-over-year increase of 67.59%. This contributed to the annual value of -$0.00 for FY2024, which is 106.49% down from last year.
- According to the latest figures from Q2 2023, RedHill Biopharma's EPS (Basic) is $0.05, which was up 502.62% from -$0.01 recorded in Q1 2023.
- RedHill Biopharma's 5-year EPS (Basic) high stood at $0.11 for Q4 2020, and its period low was -$0.31 during Q4 2021.
- Over the past 3 years, RedHill Biopharma's median EPS (Basic) value was $0.01 (recorded in 2022), while the average stood at -$0.04.
- Per our database at Business Quant, RedHill Biopharma's EPS (Basic) surged by 167.41% in 2020 and then slumped by 378.20% in 2021.
- Quarterly analysis of 5 years shows RedHill Biopharma's EPS (Basic) stood at $0.04 in 2019, then spiked by 167.41% to $0.11 in 2020, then slumped by 378.20% to -$0.31 in 2021, then surged by 64.92% to -$0.11 in 2022, then spiked by 163.44% to $0.05 in 2023.
- Its EPS (Basic) stands at $0.05 for Q2 2023, versus -$0.01 for Q1 2023 and -$0.11 for Q4 2022.